Literature DB >> 32916266

Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer.

P Heudel1, S Chabaud2, D Perol2, I Ray-Coquard1, J-Y Blay3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32916266     DOI： 10.1016/j.annonc.2020.09.001

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Hematologic malignancies following immune checkpoint inhibition for solid tumors.

Authors:  Mick J M van Eijs; Lotte E van der Wagen; Rogier Mous; Roos J Leguit; Lisette van de Corput; Anne S R van Lindert; Britt B M Suelmann; Anna M Kamphuis; Stefan Nierkens; Karijn P M Suijkerbuijk
Journal:  Cancer Immunol Immunother       Date:  2022-06-13       Impact factor: 6.630

2.  Second primary tumor after immune checkpoint inhibitor therapy: A case report.

Authors:  Kang Miao; Shuangni Yu; Jun Ni; Xiaotong Zhang; Li Zhang
Journal:  Thorac Cancer       Date:  2022-02-11       Impact factor: 3.500
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.